Literature DB >> 32998975

Progression of chronic kidney disease in familial LCAT deficiency: a follow-up of the Italian cohort.

Chiara Pavanello1, Alice Ossoli1, Marcello Arca2, Laura D'Erasmo2, Giuliano Boscutti3, Loreto Gesualdo4, Tiziano Lucchi5, Tiziana Sampietro6, Fabrizio Veglia7, Laura Calabresi8.   

Abstract

Familial LCAT deficiency (FLD) is a rare genetic disorder of HDL metabolism, caused by loss-of-function mutations in the LCAT gene and characterized by a variety of symptoms including corneal opacities and kidney failure. Renal disease represents the leading cause of morbidity and mortality in FLD cases. However, the prognosis is not known and the rate of deterioration of kidney function is variable and unpredictable from patient to patient. In this article, we present data from a follow-up of the large Italian cohort of FLD patients, who have been followed for an average of 12 years. We show that renal failure occurs at the median age of 46 years, with a median time to a second recurrence of 10 years. Additionally, we identify high plasma unesterified cholesterol level as a predicting factor for rapid deterioration of kidney function. In conclusion, this study highlights the severe consequences of FLD, underlines the need of correct early diagnosis and referral of patients to specialized centers, and highlights the urgency for effective treatments to prevent or slow renal disease in patients with LCAT deficiency.
Copyright © 2020 Pavanello et al.

Entities:  

Keywords:  cholesterol/metabolism; familial lecithin:cholesterol acyltransferase deficiency; high density lipoprotein; kidney transplantation; lecithin:cholesterol acyltransferase; lipoproteins; renal disease

Year:  2020        PMID: 32998975      PMCID: PMC7707181          DOI: 10.1194/jlr.P120000976

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  22 in total

1.  Uptake and metabolism of lipoprotein-X in mesangial cells.

Authors:  E G Lynn; P C Choy; A Magil; K O
Journal:  Mol Cell Biochem       Date:  1997-10       Impact factor: 3.396

2.  Long-term outcome of kidney transplantation in AL amyloidosis.

Authors:  Avital Angel-Korman; Lauren Stern; Shayna Sarosiek; J Mark Sloan; Gheorghe Doros; Vaishali Sanchorawala; Andrea Havasi
Journal:  Kidney Int       Date:  2018-12-21       Impact factor: 10.612

3.  Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study.

Authors:  Robert D Shamburek; Rebecca Bakker-Arkema; Alexandra M Shamburek; Lita A Freeman; Marcelo J Amar; Bruce Auerbach; Brian R Krause; Reynold Homan; Steve J Adelman; Heidi L Collins; Maureen Sampson; Anna Wolska; Alan T Remaley
Journal:  Circ Res       Date:  2015-12-01       Impact factor: 17.367

4.  Proteinuria in early childhood due to familial LCAT deficiency caused by loss of a disulfide bond in lecithin:cholesterol acyl transferase.

Authors:  A G Holleboom; J A Kuivenhoven; C C van Olden; J Peter; A W Schimmel; J H Levels; R M Valentijn; P Vos; J C Defesche; J J P Kastelein; G K Hovingh; E S G Stroes; C E M Hollak
Journal:  Atherosclerosis       Date:  2011-01-21       Impact factor: 5.162

5.  Possible induction of renal dysfunction in patients with lecithin:cholesterol acyltransferase deficiency by oxidized phosphatidylcholine in glomeruli.

Authors:  S Jimi; N Uesugi; K Saku; H Itabe; B Zhang; K Arakawa; S Takebayashi
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

6.  Characterization of a new LCAT mutation causing familial LCAT deficiency (FLD) and the role of APOE as a modifier gene of the FLD phenotype.

Authors:  Alexis Baass; Hanny Wassef; Michel Tremblay; Lise Bernier; Robert Dufour; Jean Davignon
Journal:  Atherosclerosis       Date:  2009-05-21       Impact factor: 5.162

7.  Lecithin:Cholesterol Acyltransferase Activation by Sulfhydryl-Reactive Small Molecules: Role of Cysteine-31.

Authors:  Lita A Freeman; Stephen J Demosky; Monika Konaklieva; Rostislav Kuskovsky; Angel Aponte; Alice F Ossoli; Scott M Gordon; Ross F Koby; Kelly A Manthei; Min Shen; Boris L Vaisman; Robert D Shamburek; Ajit Jadhav; Laura Calabresi; Marjan Gucek; John J G Tesmer; Rodney L Levine; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2017-06-02       Impact factor: 4.030

8.  A new equation to estimate glomerular filtration rate.

Authors:  Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

9.  Lipoprotein X Causes Renal Disease in LCAT Deficiency.

Authors:  Alice Ossoli; Edward B Neufeld; Seth G Thacker; Boris Vaisman; Milton Pryor; Lita A Freeman; Christine A Brantner; Irina Baranova; Nicolás O Francone; Stephen J Demosky; Cecilia Vitali; Monica Locatelli; Mauro Abbate; Carlamaria Zoja; Guido Franceschini; Laura Calabresi; Alan T Remaley
Journal:  PLoS One       Date:  2016-02-26       Impact factor: 3.240

10.  The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families.

Authors:  Laura Calabresi; Livia Pisciotta; Anna Costantin; Ilaria Frigerio; Ivano Eberini; Paola Alessandrini; Marcello Arca; Gabriele Bittolo Bon; Giuliano Boscutti; Ghil Busnach; Giovanni Frascà; Loreto Gesualdo; Maddalena Gigante; Graziana Lupattelli; Anna Montali; Stefano Pizzolitto; Ivana Rabbone; Marina Rolleri; Giacomo Ruotolo; Tiziana Sampietro; Adalberto Sessa; Gaetano Vaudo; Alfredo Cantafora; Fabrizio Veglia; Sebastiano Calandra; Stefano Bertolini; Guido Franceschini
Journal:  Arterioscler Thromb Vasc Biol       Date:  2005-06-30       Impact factor: 8.311

View more
  4 in total

Review 1.  Current Status of Familial LCAT Deficiency in Japan.

Authors:  Masayuki Kuroda; Hideaki Bujo; Koutaro Yokote; Takeyoshi Murano; Takashi Yamaguchi; Masatsune Ogura; Katsunori Ikewaki; Masahiro Koseki; Yasuo Takeuchi; Atsuko Nakatsuka; Mika Hori; Kota Matsuki; Takashi Miida; Shinji Yokoyama; Jun Wada; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2021-04-18       Impact factor: 4.928

2.  The HDL mimetic CER-001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency.

Authors:  Chiara Pavanello; Marta Turri; Arianna Strazzella; Patrizia Tulissi; Stefano Pizzolitto; Giovanna De Maglio; Riccardo Nappi; Laura Calabresi; Giuliano Boscutti
Journal:  J Intern Med       Date:  2021-11-11       Impact factor: 13.068

Review 3.  High-Density Lipoproteins and the Kidney.

Authors:  Arianna Strazzella; Alice Ossoli; Laura Calabresi
Journal:  Cells       Date:  2021-03-31       Impact factor: 6.600

Review 4.  A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency.

Authors:  Cecilia Vitali; Archna Bajaj; Christina Nguyen; Jill Schnall; Jinbo Chen; Kostas Stylianou; Daniel J Rader; Marina Cuchel
Journal:  J Lipid Res       Date:  2022-01-20       Impact factor: 5.922

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.